The AcrySof IQ Panoptix intraocular lens is able to restore visual function with an acceptable intermediate and near vision after cataract surgery with good contrast sensitivity and an improvement in the near activity visual questionnaire.

PurposeThe aim of this work is to review the lenses, assessing their advantages and disadvantages. We describe a total of seven types of intraocular lenses (IOLs) recommended for age-related macular degeneration (AMD).MethodsWe used the PubMed web platform to search for implantable devices in various stages of AMD. We searched for both prospective and retrospective studies and also case reports.ResultsClinical results in AMD patients have been described for a total of seven types of IOLs recommended for AMD: an implantable miniature telescope (IMT), IOL-VIP System, Lipshitz macular implant (LMI), sulcus-implanted Lipshitz macular implant, LMI-SI, Fresnel Prism Intraocular Lens, iolAMD and Scharioth Macula Lens.ConclusionsWe conclude that to objectively ascertain the effectiveness and safety of these lenses, further independent clinical studies with longer follow-up data are necessary prior to the general use of these optical devices.

Both schedules achieved similar results improving BCVA, though the second group required a lower number of injections, showing a higher rate of recurrences during the first year.

Purpose: To describe the anatomical and visual outcome of subfoveal and juxtafoveal choroidal neovascularization (CNV) in highly myopic (HM) eyes treated with intravitreal bevacizumab Methods: Prospective, non randomized, multicentric, interventional case series. 17 highly myopic eyes from 16 patients with subfoveal or juxtafoveal choroidal neovascularization were treated by three monthly intravitreal injections with 1.25 mg bevacizumab. Patients were evaluated for best corrected visual acuity (BCVA) and optical coherence tomography (OCT) at baseline, and monthly before the injections were performed. Fluorescein angiography (FA) was performed at baseline and at month 3 Results: Patients averaged 48.1 years‐of‐age (SD 15.3; range 29 to 72). Five patients were males and 11 were females. All eyes were followed for six months or longer. BCVA at baseline averaged 20/67 (range 20/160 to 20/32) (61.0 letters, SD 10, range 40 to 75) and 20/48 (range 20/125 to 20/20) (69.6 letters, SD 12.6, range 45 to 85) at the end of follow‐up (p=0.003 and p=0.002 respectively). Average central foveal thickness was (CFT) 253.5 microns (SD 40.1, range 205 to 340) at baseline and 202.1 microns (SD 31.7; range 154 to 251) at the end (p=0.001). Leakage from CNV ceased in all eyes at month three. No ocular or systemic safety issues appeared during follow‐up Conclusions: Intravitreal bevacizumab seems to be an effective and safe therapeutical procedure to treat subfoveal or juxtafoveal CNV in HM eyes. Further studies are required to verify the efficacy and usefulness of this therapy compared with established treatments for CNV in HM eyes